Vieira-Sebe N, Almeida-Parra F, Ranz-Colio A, Moreno-Moreno E, Julio Acero-Sanz 1,2,4 . Metastasis of oncocytic thyroid carcinoma in the mandibular condyle: An exceptional localization. J Clin Exp Dent. 2025;17(5):e614-8.

doi:10.4317/jced.62635

References

1. Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, et al. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. JAMA Otolaryngol Head Neck Surg. 2024;150(3):265-72. https://doi.org/10.1001/jamaoto.2023.4323 PMid:38206595

2. Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer: A Review. JAMA. 2024;331(5):425-35. https://doi.org/10.1001/jama.2023.26348 PMid:38319329

3. Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. Endocrinol Metab (Seoul). 2022;37(5):703-18. https://doi.org/10.3803/EnM.2022.1553 PMid:36193717 PMCid:PMC9633223

4. Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013;119(3):504-11. https://doi.org/10.1002/cncr.27770 PMid:22893587

5. Gruszczynski NR, Hasan SS, Brennan AG, De La Chapa J, Reddy AS, Martin DN, et al. Oncocytic carcinoma of the thyroid: Conclusions from a 20-year patient cohort. Head Neck. 2024;46(8):2042-7. https://doi.org/10.1002/hed.27700 PMid:38390640

6. Fiore M, Oliveri Conti G, Caltabiano R, Buffone A, Zuccarello P, Cormaci L, et al. Role of Emerging Environmental Risk Factors in Thyroid Cancer: A Brief Review. Int J Environ Res Public Health. 2019;16(7):1185. https://doi.org/10.3390/ijerph16071185 PMid:30986998 PMCid:PMC6480006

7. Mirkatouli NB, Hirota S, Yoshinaga S. Thyroid cancer risk after radiation exposure in adults-systematic review and meta-analysis. J Radiat Res. 2023;64(6):893-903. https://doi.org/10.1093/jrr/rrad073 PMid:37816676 PMCid:PMC10665305

8. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(8):925-51. https://doi.org/10.6004/jnccn.2022.0040 PMid:35948029

9. Matsuura D, Yuan A, Wang L, Ranganath R, Adilbay D, Harries V, et al. Follicular and Hurthle Cell Carcinoma: Comparison of Clinicopathological Features and Clinical Outcomes. Thyroid. 2022;32(3):245-54. https://doi.org/10.1089/thy.2021.0424 PMid:35078345 PMCid:PMC9206490

10. Humphreys BM, Memeh KO, Funkhouser A, Vaghaiwalla TM. Prognostic factors and survival analysis of Hurthle cell carcinoma: A population-based study. Surgery. 2022;172(5):1379-84. https://doi.org/10.1016/j.surg.2022.07.007 PMid:36038373

11. Ahmadi S, Stang M, Jiang XS, Sosa JA. Hürthle cell carcinoma: current perspectives. Onco Targets Ther. 2016;9:6873-84. https://doi.org/10.2147/OTT.S119980 PMid:27853381 PMCid:PMC5106236

12. Besic N, Schwarzbartl-Pevec A, Vidergar-Kralj B, Crnic T, Gazic B, Marolt Music M. Treatment and outcome of 32 patients with distant metastases of Hürthle cell thyroid carcinoma: a single-institution experience. BMC Cancer. 2016;16:162. https://doi.org/10.1186/s12885-016-2179-3 PMid:26921186 PMCid:PMC4768323

13. Khan S, Sharibi A, Neff R, Grace W, Young IS. Metastatic Hürthle cell carcinoma: a unique case report and review of the literature. Endocr Pract. 2005;11(4):285-9. https://doi.org/10.4158/EP.11.4.285 PMid:16006295

14. Zhang H, Zeng L, Liang C, Qiu H, Zhang M, Zhu Y, et al. Successful treatment of Hurthle cell thyroid carcinoma with lung and liver metastasis using docetaxel and cisplatin. Jpn J Clin Oncol. 2012;42(11):1086-90. https://doi.org/10.1093/jjco/hys146 PMid:22984126

15. Haugen BR. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. https://doi.org/10.1089/thy.2015.0020 PMid:26462967 PMCid:PMC4739132

16. Santa María V, Candelino G, Rubino A, Gonzalez-Aguilar O, Marteletti C, González JA. Factores de riesgo y supervivencia en el carcinoma de células de Hürthle. Revisión sistemática y metanálisis. Rev Argent Cir. 2021;113(1):9-23.

17. Besic N, Vidergar-Kralj B, Frkovic-Grazio S, Movrin-Stanovnik T, Auersperg M. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid. Thyroid. 2003;13(6):577-84. https://doi.org/10.1089/105072503322238845 PMid:12930602

18. Chiapponi C, Hartmann MJM, Schmidt M, Faust M, Bruns CJ, Schultheis AM, et al. Hürthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature. Front Endocrinol (Lausanne). 2022;13:904986. https://doi.org/10.3389/fendo.2022.904986 PMid:35846317 PMCid:PMC9276955

19. Hameed NUF, Hoppe MM, Habib A, Head J, Shanahan R, Gross BA, et al. Surgical management of metastatic Hürthle cell carcinoma to the skull base, cortex, and spine: illustrative case. J Neurosurg Case Lessons. 2023;6(15):CASE23263. https://doi.org/10.3171/CASE23263 PMid:37910014 PMCid:PMC10566523

20. Bhandari P, Shrivastava T, Pawar P. Oncocytic (Hurthle Cell) Thyroid Carcinoma Metastasis To Mandible: a Rare Case Report. Indian J Appl Res. 2021;30-31. https://doi.org/10.36106/ijar/0201259

21. Jillard CL, Youngwirth L, Scheri RP, Roman S, Sosa JA. Radioactive Iodine Treatment Is Associated with Improved Survival for Patients with Hürthle Cell Carcinoma. Thyroid. 2016 Jul;26(7):959-64. https://doi.org/10.1089/thy.2016.0246 PMid:27150319